Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
Status:
Not yet recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
The goal of this phase I/II clinical trial is to test in relapsed or refractory acute
lymphoblastic leukemia (R/R ALL) patients undergoing allogeneic hemopoietic stem-cell
transplantation (allo-HSCT). The main question it aims to answer is:
• The efficacy and safety of blinatumomab maintenance therapy in reducing the recurrence rate
a in R/R ALL patients after allo-HSCT. Participants will take intravenous blinatumomab after
allo-HSCT. The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous
drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment
with blinatumomab was initiated within 60 to 90 days after transplantation and was
administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was
administered 1 hour before administration on days 1 and 3 to prevent adverse events.